Actively Recruiting
Phase 1 Open-Label Study Evaluating Safety, Tolerability, and Pharmacokinetics of HSK46256 Tablets in Patients With Advanced Solid Tumors
Led by Haisco Pharmaceutical Group Co., Ltd. · Updated on 2026-10-27
275
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying HSK46256, a selective PARP1 inhibitor, in patients with advanced solid tumors. This Phase 1, open-label, multicenter trial aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of this drug. The study includes a dose escalation phase followed by a dose expansion phase to assess appropriate dosing and preliminary effectiveness. Participants will take HSK46256 tablets orally once daily, except during a single-dose period in dose escalation. The dose escalation phase uses a 33 design to test multiple dose levels, while the dose expansion phase enrolls patients at selected doses to further evaluate safety and early signs of benefit. Treatment continues until disease progression or intolerable side effects. Throughout the study, participants will undergo assessments to monitor dose-limiting toxicities and determine the maximum tolerated dose up to 24 days. Additional outcomes include progression-free survival, duration of response, disease control rate, and pharmacokinetic measurements over up to 24 months. Safety and tolerability will be closely monitored during treatment, with overall participation lasting until treatment discontinuation or disease progression.
CONDITIONS
Brief Title
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of HSK46256 in Patients With Advanced Solid Tumors
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here